Introduction
============

Hepatitis B virus (HBV) infection is a global health concern \[[@B1]\]. Acute HBV infection can cause severe acute hepatitis B that can rapidly progress to acute liver failure (ALF), which results in death or transplantation in 80% of relative individuals \[[@B2]\]. ALF is a life-threatening disease characterized by rapid deterioration of liver function in a patient without previously recognized liver disease. China is a particularly endemic area for HBV infection \[[@B3]\]; however, up to now, no extensive investigation on ALF has been carried out and thus no representative data are available in China. Recently, we performed a multi-center investigation of ALF in Chinese population and found out 11 cases with ALF caused by severe acute hepatitis B. Because of its rarity, studies on this disease are much fewer. Here, we reported the clinical features and prognosis of these cases.

Patients and methods
--------------------

### Patient collection

ALF in this study was defined as coagulopathy (prothrombin activity (PTA) ≤ 40% or international normalized ratio (INR) ≥ 1.5), jaundice (serum total bilirubin (TBil) ≥171 μmol/L) and encephalopathy (any degree of altered mentation) within 4 weeks in a patient without pre-existing liver diseases. The diagnosis of acute hepatitis B was based on the detection of HBsAg (or serum HBV DNA) and immunoglobulin M antibody to hepatitis B core antigen (Figure [1](#F1){ref-type="fig"}). Patients with ALF caused by severe acute hepatitis B between January 2007 and December 2012 were enrolled in this study. None of these patients had coinfection with hepatitis D virus.
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Seven tertiary military hospitals in different areas of China were included in this investigation: Beijing 302 Hospital, PLA General Hospital, Changhai Hospital Affiliated to Second Military Medical University, PLA 161 Hospital, PLA 477 Hospital, General Hospital of Jinan Military Region and General Hospital of Lanzhou Military Region.

The study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committees of each hospital. Informed consent was obtained from all patients or guardians for being included in the study.

### Data extraction and assessment

Demographic and clinical data were obtained from the electronic medical records and follow-up documents. Grade of HE had been determined in the medical records according to the widely-accepted following criteria in China \[[@B4]\]: I. loss of sleep rhythm, anxiousness, confusion or flapping tremors; II. loss of sphincter control, drowsiness or behavioral disorder; III. persistent coma, but still responding to shouts; IV. deep coma with no consciousness.

Findings
========

Demographic and clinical features on admission
----------------------------------------------

Of the 11 patients, 10 were male and 1 was female, and 9 had positive and 2 had negative hepatitis B e antigen. None of these patients had the history of excessive drinking. Other demographic and entry laboratory characteristics of these patients including age, grade of HE, white blood cell count, hemoglobin, platelet count, PTA, INR, serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP), serum cholinesterase, serum lactate dehydrogenase (LDH), serum TBil, serum albumin, serum creatinine, serum urea nitrogen (UN), serum glucose, serum Na^+^, serum K^+^, serum Cl^−^ and arterial blood ammonia (BLA) are summarized in Table [1](#T1){ref-type="table"}.

###### 

Clinical characteristics of patients with ALF on admission and outcomes

  **Parameters**                                              **Patient 1**   **Patient 2**   **Patient 3**   **Patient 4**   **Patient 5**   **Patient 6**   **Patient 7**   **Patient 8**   **Patient 9**   **Patient 10**   **Patient 11**
  ----------------------------------------------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------- ----------------
  Sex                                                         male            male            male            male            male            female          male            male            male            male             male
  Outcome                                                     death           survive         death           death           survive         survive         death           survive         death           death            death
  Age (years)                                                 70              27              28              58              50              55              44              26              39              47               47
  Body Mass Index (kg/m^2^)                                   26.12           23.94           24.49           23.25           27.44           22.15           24.34           26.23           22.02           24.62            27.18
  Grade of HE                                                 4               2               3               3               1               3               3               1               3               4                3
  Days from onset of illness to outcome (death or recovery)   16              10              4               3               14              20              10              11              7               4                10
  Serum ALT (U/L)                                             1303            2000            4679            2917            941             1333            1645            3562            1164            1886             8294
  Serum AST (U/L)                                             664             1700            5111            3975            758             447             922             2277            516             155              6486
  Serum TBil (μmol/L)                                         225.2           463.1           173.5           180.6           386.3           173.6           216.0           179.0           194.2           173.9            215.0
  Serum ALP (U/L)                                             183             144             129             217             175             159             222             164             202             144              266
  Serum LDH (U/L)                                             230             138             1015            334             324             391             233             354             212             330              608
  Serum Albumin (g/L)                                         33              32              31              35              28              25              28              40              37              29               38
  Serum glucose (mmol/L)                                      7.6             2.5             12.1            17.5            2.3             3.8             11.0            4.8             3.1             10.5             4.3
  Serum creatinine (μmol/L)                                   117             58              97              168             118             69              95              68              77              90               92
  Serum UN (mmol/L)                                           4.8             3.3             3.0             1.9             6.1             2.5             1.8             1.5             4.3             1.7              2.7
  Serum Na^+^ (mmol/L)                                        135             138             137             133             135             139             133             140             137             137              132
  Serum K^+^ (mmol/L)                                         4.5             3.8             3.8             4.8             4.5             3.0             3.9             3.8             3.8             4.2              4.0
  Serum Cl^−^ (mmol/L)                                        103.1           105.8           103.2           103.9           98.6            106.5           106.0           102.7           101.3           108.6            95.7
  Serum HBV DNA (IU/mL)                                       5.02 × 10^4^    1.00 × 10^3^    6.32 × 10^8^    3.23 × 10^4^    2.63 × 10^5^    1.27 × 10^4^    3.22 × 10^7^    2.19 × 10^5^    6.20 × 10^9^    1.49 × 10^3^     1.54 × 10^3^
  White blood cell count (×10^9^)                             4.06            3.24            9.62            12.16           7.3             5.31            6.11            6.7             11.89           12.47            11.17
  Platelet count (×10^9^)                                     149             122             87              88              97              44              66              147             120             29               38
  Hemoglobin                                                  129             103             138             144             137             105             127             151             138             140              148
  PTA (%)                                                     34              30              11              6.68            21.4            21.1            20              33              19.8            21               15
  INR                                                         1.60            1.92            3.53            5.49            2.52            2.39            2.77            1.63            2.40            2.45             2.89
  Arterial BLA (μmol/L)                                       84              71              102             217             52              69              118             67              64              173              273

*ALF*, Acute liver failure; *HE*, Hepatic encephalopathy; *ALT,* Alanine aminotransferase; *AST*, Aspartate aminotransferase; total bilirubin; *ALP*, Alkaline phosphatase; *LDH*, Lactate dehydrogenase; *CHE*, Cholinesterase; *UN*, Urea nitrogen; *PTA*, Prothrombin activity; *INR*, International normalized ratio; *BLA*, Blood ammonia.

Treatment, complications and outcomes
-------------------------------------

Patient 1, Patient 5 and Patient 10 received antiviral therapy with lamivudine and Patient 6 received antiviral treatment with entecavir at the diagnosis of acute hepatitis B. The other patients did not receive any antiviral treatment in the period of intensive care. Sera from Patient 5 and Patient 6 were sent to undergo the HBV reverse-transcriptase gene amplification and sequencing at the diagnosis with the method previously described by us \[[@B5]\], and no nucleos(t)ide-resistant mutant was reported.

During the clinical course, most significantly, serum TBil levels in non-survivors worsened during days 2 to 6 after admission, while levels in survivors improved during the same period. Other indicators did not exhibit especially interesting features.

As serious complications, sepsis occurred in 3 patients and apparent hemorrhage could be observed in 9 patients, 3 (Patient 3, Patient 4 and Patient 10) of whom developed diffuse alveolar hemorrhage. In these 11 patients, 4 survived (Patient 2, Patient 5, Patient 6 and Patient 8) and 7 finally died. 4 died of hemorrhage, 2 died of systemic inflammatory response syndrome and 1 died of irreversible coma. No patients received liver transplantation.

Discussion
==========

Severe acute hepatitis B is an important cause of ALF worldwide \[[@B6]\]. In real-world practice, a tough but vital problem that physicians often encounter is the differentiation between acute hepatitis B and acute exacerbation of chronic HBV infection. In order to ensure the accuracy of diagnosis in this study, we looked through the past status of hepatitis B surface antigen for each included patient and excluded any patient who could be identified or seemed to have acute exacerbation of chronic HBV infection.

Overall, the morbidity of ALF was more common in the female than that in the male \[[@B7]\]. However, according to our study, men were affected by HBV-related ALF more often than women. Regarding the treatment, contradictions still exist among different studies \[[@B8]\]. A randomized controlled trial from India concluded that though lamivudine (100 mg per day) caused a greater decrease in levels of HBV DNA, it did not cause significantly greater biochemical and clinical improvement as compared to placebo in patients with severe acute hepatitis B \[[@B9]\]. Another study from China reported that early treatment with lamivudine led to a greater decrease in HBV DNA level, better clinical improvement and mortality improvement in patients with severe acute hepatitis B \[[@B10]\]. For our study, in the 4 patients who received antiviral therapy, 2 died and 2 survived, while in the other 7 patients who did not receive antiviral treatment, 5 died and 2 survived. Whether antiviral treatment is necessary for ALF caused by severe acute hepatitis B needs further extensive studies, but the obstacle is big because a randomized trial in the setting of severe acute hepatitis B seems unethical.

In this study, the mortality was very high and all patients who died had HE grade 3 to 4, suggesting a more advanced disease progression in these patients. Additionally, heavy bleeding is always the most frequent but refractory complication in patients with ALF \[[@B11]\]. Hemorrhage attributed to the main cause of mortality in this investigation. The only treatment option for hemorrhage is blood transfusion in China. However, shortage of blood usually leads to dismal outcomes. On the other hand, the rate of liver transplantation in this investigation was null, though it remained the effective treatment in ALF when standard medical therapy failed. The reasons for this included the difficulties in obtaining organs in urgent fashion, as well as the economic situation of patients in China. Shortage of transplantation also resulted in the high mortality of ALF.

In summary, we reported the rare clinical entity of ALF caused by severe acute hepatitis B. Hemorrhage was the most common complication and cause of death. For these critically ill patients, coagulopathy is a vital problem in the intensive care.
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